Expression of SATB1 protein in the ductal breast carcinoma tissue microarrays — preliminary study by Kobierzycki, Christopher et al.
FOLIA HISTOCHEMICA
ET CYTOBIOLOGICA
Vol. 51, No. 4, 2013
pp. 333–338
©Polish Society for Histochemistry and Cytochemistry
Folia Histochem Cytobiol. 2013
10.5603/FHC.2013.0045
www.fhc.viamedica.pl
ORIGINAL STUDY
Correspondence address: C. Kobierzycki, Department  
of Histology and Embryology, Wroclaw Medical University 
Chalubinskiego St. 6a, 50–368 Wroclaw, Poland  
tel.: +48 71 784 16 82, fax: +48 71 784 00 82; 
e-mail: christopher.kobierzycki@umed.wroc.pl
Expression of SATB1 protein in the ductal breast  
carcinoma tissue microarrays — preliminary study
Christopher Kobierzycki1, Andrzej Wojnar2, Piotr Dziegiel1, 3
1Department of Histology and Embryology, Wroclaw Medical University, Wroclaw, Poland
2Department of Pathomorphology, Lower Silesian Oncology Centre, Wroclaw, Poland
3Department of Physiotherapy, University School of Physical Education, Wroclaw, Poland
Abstract: Special AT-rich sequence-binding protein 1 (SATB1) is a nuclear matrix protein which interacts with 
specific regions of DNA, ensuring its proper organization and function in the cell. The expression of SATB1 
was primarily found in thymocytes, but its increased levels were observed in various types of cancers. However, 
the knowledge of the function and application possibilities of this protein is still limited. The aim of this study 
was to investigate the expression of SATB1 protein using immunohistochemistry and tissue microarray (TMA) 
technique and determine its possible relationship with the proliferative marker Ki-67, estrogen a (ER) and pro-
gesterone (PR) receptors as well as grade of histological malignancy (G). The study was performed on material 
of 48 archival invasive ductal breast cancers (IDC). The TMAs were prepared with the use of 0.6 mm diameter 
punches. Immunohistochemical reactions were carried out using antibodies against Ki-67, ER, PR and SATB1 
proteins. The intensity of the nuclear reaction was evaluated using a light microscope and computer-assisted image 
analysis. Expression of Ki-67 and SATB1 protein was observed in 89.58% and 31.25% of cancer cases, respec-
tively. 62.5% of tumors were classified as ER-positive, and 47.92% as PR-positive. Statistical analysis showed a 
moderate positive correlation between Ki-67 and SATB1 expression (r = 0.291, p = 0.045 independently on the 
receptor status, and r = 0.392, p = 0.032 in ER-negative tumors). The expression of the Ki-67 antigen increased 
with higher grade of histological malignancy (G). The results suggest that SATB1 protein may play an indirect 
role in the cell proliferation and should be evaluated in relation to the other markers. Further studies concern-
ing determination of its role in cancer progression and metastasis, in terms of application as therapeutic target 
and prognostic marker, are recommended. (Folia Histochemica et Cytobiologica 2013, Vol. 51, No. 4, 333–338)
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Introduction
Malignant transformation of cells is associated with 
changes in gene expression. Gross alterations in 
chromatin organization may be involved in many 
gene dysregulations, as well as the involvement of 
specific transcription factors [1, 2]. Specialized ge-
nomic DNA segments that exhibit high affinity to 
the nuclear matrix in vitro have been designated as 
matrix/scaffold attachment regions (MARs/SARs). 
They have been proposed to create a unique nuclear 
microenvironment rich in regulatory proteins able 
to sustain DNA transcription, replication, repair, 
and recombination [3, 4]. During investigations on 
potential mechanisms that could lead to significant 
alterations in gene expression in cancer cells a few 
important proteins with nuclear localization have 
been identified. Many of these proteins are drama-
tically up-regulated in human malignancies. They 
provide not only an architectural core but also recruit 
functional multi-molecular complexes at the base of 
chromatin loops to affect multiple distant genes [5, 6]. 
Experimental strategies by which these proteins can 
be exploited as carcinoma-specific diagnostic markers 
and as targets for antineoplastic therapy have been 
discussed [3].
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Special AT-rich sequence binding protein 1 
(SATB1) is a genome organizer protein that fa-
cilitates various intracellular processes, providing 
a nuclear architectural platform that binds hundreds 
of genes, through its interaction with specific genomic 
sequences; this activity allows expression of these 
genes to be regulated in parallel, and, thus, to alter 
cell functions [7]. SATB1 as a MAR-binding protein 
regulates the genes by folding chromatin into loop 
domain [8]. It was found to regulate gene expression 
in thymocytes and pre B-cells [9], but recent studies 
have shown that SATB1 promotes tumor growth and 
metastasis through chromatin gene recombination in 
many neoplasms such as breast, gastrointestinal tract 
(predominantly colorectal region), liver, laryngeal, 
lung, thyroid, urinary bladder, ovarian and prostate 
cancers, melanomas, osteosarcomas, gliomas and 
some types of leukemias [10–26]. Furthermore, ex-
cept SATB1 involvement in tumor progression by its 
mRNA and protein overexpression in some cancers, 
e.g. in colorectal cancer, significantly lower protein 
levels were found to be a marker of poor prognosis 
[12, 27, 28]. All of these findings strongly imply that 
SATB1 is a possible candidate oncogene that may 
contribute to carcinogenesis.
The majority of studies on SATB1 expression in 
breast cancer have been based on mRNA testing 
[29], while the use of immunohistochemical method 
has been rather limited [30]. Moreover, it seems that 
the immunohistochemistry performed on tissue mi-
croarrays (TMA-IHC method) should be abundantly 
implemented to laboratory studies, because of all its 
advantages (reaction environment standardization, 
reagents, time and money savings etc.) [31, 32]. For 
this reason we decided to apply TMA-IHC meth-
odology to check for possible associations between 
SATB1 protein expression with other markers and 
clinicopathological features. 
Material and methods
Patients. The study was performed on material of 48 archival 
invasive ductal breast cancers (IDC), sampled in year 2000 
during procedures of mammectomy in the Lower Silesian On-
cology Centre in Wroclaw. All the patients were of female sex 
and grade of malignancy G was evaluated to be G1 in 10 cases, 
G2 in 28 cases and G3 in 10 cases (according to the 2003 World 
Health Organization (WHO) classification) [33]. The age of 
the patients ranged from 30 to 83 years (mean 56 ± 11.1 years).
Tissue microarray construction. For the construction of 
the tissue microarray blocks, a 7 µm thick section was made 
from paraffin donor block and stained with hematoxylin 
and eosin (HE). The HE sections were examined by two 
independent pathologists under light microscope (BX-41, 
Olympus, Tokyo, Japan) and areas of interest were circled 
using a permanent marker. From the corresponding paraffin 
blocks, 0.6 mm core punches were taken for each case using 
the Manual Tissue Arrayer I (Beecher Instruments Inc., 
Sun Praire, WI, USA) and transferred into the recipient 
paraffin block. 
Immunohistochemistry. Immunohistochemical (IHC) 
reactions were performed on 4 µm thick paraffin sections 
obtained from TMA blocks. The sections were dewaxed, 
re-hydrated and the epitopes were exposed using Pre-Treat-
ment Link Rinse Station and Target Retrieval Solution 
(pH 6 for Ki-67, ER and PR; pH 9 for SATB1; 97°C, 20 
min) (DakoCytomation, Glostrup, Denmark). Activity of 
endogenous peroxidase was blocked by 5 min exposure 
to Peroxidase-Blocking Reagent (DakoCytomation). The 
sections were then rinsed with Wash Buffer and incubated 
for 20 min at room temperature with the following primary 
monoclonal antibodies against Ki-67 (clone MIB-1; Mouse; 
Ready-to-use; DakoCytomation), ER (clone 1D5; Mouse; 
Ready-to-use; DakoCytomation), PR (clone PgR 636; 
Mouse; Ready-to-use; DakoCytomation) and SATB1 (clone 
EPR3895; Rabbit; 1:100; Abcam, Cambridge, UK). Sec-
ondary goat antibodies coupled to a dextran core, linked to 
horseradish peroxidase, were applied and subsequent visual-
ization was performed using the EnVision™ FLEX+ system 
(DakoCytomation) according to the manufacturer’s instruc-
tions. All IHC reactions were performed in an automated 
staining platform, Autostainer Link48 (DakoCytomation). 
The reactions were visualized using 3,3’-diaminobenzidine 
tetrachlorohydrate (DAB+ Chromogen, DakoCytomation). 
All slides were counterstained with Mayer’s hematoxylin.
Evaluation of the immunohistochemical reactions. For the 
evaluation of Ki-67 and SATB1 expression in each TMA 
core three fields with the highest number of tumor cells 
demonstrating positive reaction were selected (hot spots). 
The percentage of positive cells in each hot spot was evalu-
ated under ×400 magnification, scoring the brown-labeled 
cell nuclei of cancer cells (BX-41 light microscope equipped 
with CellD software for computer-assisted image analysis; 
Olympus). The general result for every sample represented 
an average of the three hot spot evaluation. The status of 
estrogen and progesterone receptors expression was asses-
sed according to their presence in the nuclei of cancer cells. 
If reaction was observed in over 10% of cancer cells it was 
classified as positive. The intensity of the IHC reactions 
in coded TMAs was independently evaluated by two pa-
thologists. Moreover, in doubtful cases, re-evaluation with 
a double-headed microscope was performed until a con-
sensus was achieved.
Statistical analysis. The results were subjected to statistical 
analysis using Prism 6.0 software (GraphPad, La Jolla, CA, 
USA). The relationship between the expressions of Ki-67 
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and SATB1 in regard to hormone receptor status was exami-
ned using Spearman’s rank correlation test. The associations 
between expression intensities of analyzed markers with 
histological malignancy grade (G) were examined by Kru-
skal-Wallis and Mann-Whitney tests. In all analyses, results 
were considered to be statistically significant when p < 0.05.
Results
IHC reactions were localized in nuclear compartment 
of the cancer cells. Expression of Ki-67 and SATB1 
protein was observed in 89.58% and 31.25% of IDCs, 
respectively. 62.5% of tumors were classified as ER
-positive, and 47.92% as PR-positive. Analysis of Ki-
67, SATB1, ER and PR expression was conducted on 
serial sections (Figure 1A, B, C, and D, respectively). 
The correlations between expression of the studied 
proteins were found to be moderate (r = 0.291, 
p = 0.045 independently on the receptor status, 
and r = 0.392, p = 0.032 in ER-negative tumors; 
Spearman’s correlation test). All correlation results 
are shown in Table 1. The expression of the Ki-67 
antigen increased with higher grade of histological 
malignancy. Statistically significant differences were 
found between: G1 vs. G2 (p = 0.0002), G2 vs. G3 
(p = 0.0253), and G1 vs. G3 (p = 0.0184) (Mann-Whit-
ney test; Figure 2). Similar trend was noted in regard 
to SATB1 protein expression, but statistical signifi-
cance level has not been reached (Mann-Whitney and 
Kruskal-Wallis tests; Figure 3).
Discussion 
Cancer progression and metastasis involve series of 
alterations in the expression of multitude of genes. 
The structure and organization of chromatin play an 
important role in spatial arrangement of genes inside 
cell nucleus thereby allowing different mechanisms to 
activate or silence the transcription of genes governed 
by various epigenetic events. Epigenetic modifications 
and dynamic changes in chromatin organization by 
organizer proteins have recently been shown to play 
an instrumental role in regulating cancer-promoting 
genes [34, 35]. Aberrant expression of SATB1 mRNA 
and protein has been shown to promote growth and 
metastasis of various neoplasms [10–26]. The main 
and most quoted role of SATB1 is chromatin orga-
nization and functioning as a global regulator of gene 
expression, among others during cancer development 
(e.g. it directly regulates the expression of ERRB2, 
MMP2, ABL1, and E-cadherin) [34, 36]. The expres-
sion of SATB1 progressively increases with the pro-
gression of cancer and it was suggested that SATB1 
dynamically reprograms the expression of genes that 
are involved in carcinogenesis, e.g. by determining 
specific epigenetic modifications at target gene loci 
Figure 1. Nuclear expression of Ki-67 (A), SATB1 (B), ER (C), PR (D) on serial sections of invasive ductal breast carcino-
ma. Immunohistochemistry performed on tissue microarrays (TMA-IHC method); magnification ×100
A B
C D
20 µm
20 µm
20 µm
20 µm
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and directly up-regulating metastasis-associated genes 
while down-regulating tumor-suppressor genes [34]. 
As SATB1 reprograms chromatin organization and 
the transcription profiles to promote growth and 
metastasis in breast cancer, it may be presumed that 
mutation of the SATB1 gene might affect not only 
cell cycle progression but also apoptosis pathway in 
breast cancer [34].
In our study we checked the association between 
SATB1 protein expression with well-known marker 
of proliferation — Ki-67 antigen in relation to ER 
and PR status. The moderate correlation between 
analyzed markers independently to the receptor status 
found in our study in our opinion indicates the indirect 
role of this protein in the cancer cell proliferation. 
This is concomitant with results of other studies on 
SATB1 expression in cancers. E.g. Laurinavicius et al. 
[30] carried out IHC studies on tissue microarrays of 
109 patients with ductal breast carcinoma and stained 
a set of 10 IHC markers — ER, PR, HER2, Ki67, AR, 
BCL2, HIF-1a, SATB1, p53, and p16. They did not 
observe any significant associations between SATB1 
and other tested markers, except HIF-1a. The authors 
focused on clinical application of results, so they 
analyzed expression of markers according to the status 
of hormone. They implied that SATB1 and HIF-1a 
may be important markers of the disease associated 
with ER-positive cancers, whereas their biological 
and clinical significance remains to be elucidated [30]. 
Their findings seem to be contrary to our data since 
we found moderate correlation between expression 
of SATB1 and Ki-67 in ER-negative tumors. Similar 
results were shown by Patani et al. who found that high 
SATB1 expression levels occurred more often in ER-
negative cancers [29]. Towards to this observations, 
the use of SATB1 as target or prognostic marker 
for breast cancer should be viewed with caution and 
a possible confounding effect of the estrogen recep-
tor status of the tumor should be taken into account 
when analyzing the diagnostic and prognostic value 
of SATB1 [30, 37].
We additionally checked relationships between 
expressions of tested markers and grade of histological 
malignancy (G). Stronger expression of SATB1 and 
Ki-67 proteins was seen in higher grades of mali-
gnancy, but only Ki-67 association reached statistical 
significance level. Ki-67 expression confirms the cor-
rect choice of the studied group, whereas in case of 
SATB1 vs. G relation, similar results were observed 
in literature [30].
The very interesting property of SATB1, pointing 
at still not fully explored role of this protein in carci-
nogenesis, was described Han et al. [38]. They showed 
that SATB1 was expressed by aggressive breast cancer 
cells and it had high prognostic significance, indepen-
dently on lymph-node status. After knockdown of 
SATB1 in highly aggressive (MDA-MB-231) cancer 
cell line they observed a shift in the expression of 
over 1000 genes, reversal of tumorigenesis by resto-
ring breast-like acinar cell polarity and inhibition of 
tumor growth and metastasis. Moreover, the ectopic 
SATB1 expression in non-aggressive (SKBR3) cells 
led to gene expression patterns consistent with aggres-
Table 1. Correlation of expression intensities of analyzed 
markers: Ki-67 vs. SATB1 in regard to receptor status;  
Spearman’s correlation test
Correlation according 
to receptor status
R p
All tumors 0.291 0.045
ER — positive tumors 0.124 NS
ER — negative tumors 0.392 0.032
PR — positive tumors 0.133 NS
PR — negative tumors 0.366 NS
Figure 2. Expression of Ki-67 according to histological gra-
de of malignancy (G). *G1 vs. G2 (p = 0.0002), **G2 vs. G3 
(p = 0.0253), ***G1 vs. G3 (p = 0.0184); Mann-Whitney test
Figure 3. Expression of SATB1 according to histological 
grade of malignancy (G) was statistically insignificant
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sive-tumor phenotypes, acquiring metastatic activity 
[38]. However, these results were not confirmed by 
Iorns et al. [39] who conducted similar, very precise 
study, using the same breast cancer cell lines. None of 
the results obtained by Han et al. was reached, what 
highly limits drawing direct conclusions [39]. 
In summary, the evaluation of the SATB1 protein 
expression could be very useful for cancer diagnostics 
and treatment purposes if its relationships with other 
cellular proteins were further and better characteri-
zed. Our results, showing moderate correlation of 
SATB1 with Ki-67, especially in ER-negative IDCs 
suggest rather indirect role of this protein in cancer 
cell proliferation. Statistically insignificant association 
of SATB1 with grade of histological malignancy in 
relation to contrary results achieved by other authors 
indicate a need for further studies before drawing 
particular conclusions. Furthermore, understanding 
the molecular mechanisms of the regulation of SATB1 
expression would therefore be essential towards de-
signing strategies to control it. 
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